Pics 5: MDS/AML/ALL/SCT/CART

Question 1

ICC 2022 B-ALL

Answer 1

Question 2

WHO5 Precursor B-cell neoplasms

Answer 2

Question 2

IPSS-R Cytogenetic categories

Answer 2

Question 3

MDS WHO5
Genetic vs morph

Answer 3

Question 4

ICC MDS class

Answer 4

Question 5

High risk MDS Therapy algorithm

Answer 5

Question 6

MDS therapy, lower risk
Well vs one cytopenia vs multiple cytopenias

Answer 6

Question 7

MDS summary slide

Answer 7

Question 8

WHO5 AML types
AML-MR defining cytogenetic abnormalities and defining somatic mutations

Answer 8

Question 9

WHO2017 to ICC 2022 and WHO 2022
Comparing entities

Answer 9

Question 10

2022 WHO defining genetic anomalies
vs ICC 2022 Myeloid neoplasm with mutated TP53

Answer 10

Question 11

2022 ELN risk classification AML

Answer 11

Question 12

ICC AML diagnosis algorithm

Answer 12

Question 12

New targeted AML treatments, and type of therapy and target

Answer 12

Question 13

WHO5 diagnosis algorithm for AML

Answer 13

Question 14

AML/MDS predisposition genes

Answer 14

Question 15

Lococo protocol schema

Answer 15

Question 16

AML summary slide

Answer 16

Question 17

AML extra medullary disease, approach

Answer 17

Question 18

Lineage definitions by immunophenotype
B cell, T cell and ATP-ALL

Answer 18

Question 19

Newer agents for ALL
Indications

Answer 19

Question 20

ALL unique drug toxicities
Asparaginase
Steroid
Vincristine
MTX
6MP
Blina
Ino

Answer 20

Question 21

R/R B-ALL therapy options

Answer 21

Question 22

Summary Ph+ ALL

Answer 22

Question 23

anit-CD19 CAR-T in B-ALL
Trials and CAR-T name

Answer 23

Question 24

ALL summary

Answer 24

Question 25

ALL summary for frontline therapy

Answer 25

Question 26

ALL summary: relapsed disease

Answer 26

Question 27

New/coming for relapsed ALL

Answer 27

Question 28

Eligibility criterial for HCT

Answer 28

Question 29

Commonly used conditioning regimens in HCT

Answer 29

Question 30

HSCT complications by phase
What are the 5 phases
When are CNIs and their issues
Lung issues: which and when
Liver
Infections
GVHD

Answer 30

Question 31

FDA approved CAR-T products for which diseases?
Which CAR-T?

Answer 31

Question 32

cGVHD symptoms by system
Which systems have diagnostic cGVHD findings and what are they?

Answer 32

Question 33

NHL CAR-T vs SOC Auto in 2L treatment
Two trials, which CAR-Ts
Who should consider 2L CAR-T

Answer 33

Question 33

CAR-T in R/R MM

Answer 33

Question 33

Outcomes in R/R ALL, NHL, CLL and MM with CAR-T

Answer 33

Question 34

CAR-T cell toxicities to remember [5]

Answer 34

Question 35

Grading of CRS, ASBMT consensus

Answer 35

Question 36

ASBMT ICE scores
Points for what?

Answer 36

Question 37

ICANS mgmt

Answer 37

Question 38

CAR-T summary slide
Indications?
Mechanisms of resistance and relapse [4]

Answer 38

Question 39

Indications for Allo in AML

Answer 39

Question 40

CAR-T unique toxicities and mgmt summary slide

Answer 40

Question 41

2022 ELN risk classifications for AML

Answer 41

Question 42

Allo indications for ALL

Answer 42

Question 43

Allo indications for MDS

Answer 43

Question 44

Allo indications for MF

Answer 44

Question 45

Allo indications for nonmalignant diseases

Answer 45

Question 46

Indications/diseases treated with Auto

Answer 46

Question 47

Types of donor sources

Answer 47

Question 48

ABO incompatibility in transplant
Which are major vs minor
What can happen in major vs. minor

Answer 48

Question 49

Common Conditioning regimens
Allo?
Auto?

Answer 49

Question 50

Toxicities of common conditioning agents

Answer 50

Question 51

aGVHD organ staging
Skin?
Liver?
Diarrhea?

Answer 51

Question 52

aGVHD overall grading
Grade 1?
Grade 4?

Answer 52

Question 53

Acute vs chronic GVHD by timeline or by symptoms?

Answer 53

By symptoms!
Late acute
Chronic overlap
Classic chronic

Question 54

Common infections by phases
Pre-engraftment
Post engraftment
Late phase

Answer 54

Question 55

HSCT key points slide

Answer 55

Question 56

HSCT board pearls slide

Answer 56